5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
• 化学式: C₁₅H₁₇N₃O₂
• 分子量: 271.31
• InChiKey: PZUOQJNJLVQKBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  70.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(1-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)-pyridin-2-amine 、 tert-butyl 4-(3-iodo-1-isopropyl-1H-pyrazol-5-yl)piperidine-1-carboxylate 、 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 以to yield product (120 mg, 59% yield)的产率得到tert-butyl 4-(3-(3-cyano-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-isopropyl-1H-pyrazol-5-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

  摘要：

  本发明提供了公式（I）的化合物及其各种实施方式，以及包含公式（I）的化合物和其各种实施方式的组合物。在公式I的化合物中，R1，R2，R3，R4，R5，R6和R7基团的含义如本文所述。本发明还提供了使用公式I的化合物和包含公式（I）的化合物的组合物作为DLK抑制剂和治疗神经退行性疾病和障碍的方法。

  公开号：

  US20160002228A1

文献信息

• [EN] 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS<br/>[FR] PYRAZOLES 3 SUBSTITUÉS ET UTILISATION EN TANT QU'INHIBITEURS DE DLK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014111496A1

  公开（公告）日：2014-07-24

  The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

  本发明提供了公式（I）的化合物及其各种实施方式，以及包含公式（I）的化合物及其各种实施方式的组合物。（I）在公式I的化合物中，基团R1、R2、R3、R4、R5、R6和R7的含义如本文所述。本发明还提供了使用公式I的化合物和包含公式（I）的化合物作为DLK抑制剂以及用于治疗神经退行性疾病和紊乱的方法。
• 3-substituted pyrazoles and uses thereof
  申请人：Genentech, Inc.

  公开号：US10028942B2

  公开（公告）日：2018-07-24

  The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

  本发明提供了式（I）化合物及其各种实施方案，以及包含式（I）化合物及其各种实施方案的组合物。 在式 I 化合物中，基团 R1、R2、R3、R4、R5、R6 和 R7 的含义如本文所述。本发明还提供了使用式 I 化合物和包含式 (I) 化合物的组合物作为 DLK 抑制剂和治疗神经变性疾病和失调的方法。
• 3-SUBSTITUTED PYRAZOLES AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20170087137A1

  公开（公告）日：2017-03-30

  The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
• US9550777B2
  申请人：——

  公开号：US9550777B2

  公开（公告）日：2017-01-24
• 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS
  申请人：Genentech, Inc.

  公开号：US20160002228A1

  公开（公告）日：2016-01-07

  The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

  本发明提供了公式（I）的化合物及其各种实施方式，以及包含公式（I）的化合物和其各种实施方式的组合物。在公式I的化合物中，R1，R2，R3，R4，R5，R6和R7基团的含义如本文所述。本发明还提供了使用公式I的化合物和包含公式（I）的化合物的组合物作为DLK抑制剂和治疗神经退行性疾病和障碍的方法。